« Return to News | Technology Solutions

Cmed launches Timaeus GTB to speed study setup

Thursday, October 27, 2011 11:55 AM

Cmed Technology has launched Timaeus Guided Trial Builder (GTB), a new product that introduces an entirely different approach to reduce the time and effort required to start up electronic trials. GTB builds on a decade of real-world experience managing trials in Cmed’s CRO division. GTB enables study teams to speed up and simplify Study Setup—without sacrificing flexibility, quality or adherence to best practices.

Central to GTB is the Maximal Re-use Template (MRT) approach, which encompass all the common factors and best practices across a sponsor’s portfolio and places them in one large validated “super page.” MRTs enable rapid build of complete trials—including visit schedules, pages and complex edit checks—without any need of technical programming knowledge. They automatically ensure adherence to standards and seamlessly validate the trial during the build process, eliminating the need for manual quality control (QC) and hand-offs between teams. Adding Guided Trial Builder to Timaeus’ on-demand deployment capabilities allows study teams to start new trials and perform mid-trial updates at the touch of a button—without downtime or site interruption.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.